New combo pill aims to lower cholesterol in phase 3 trial
NCT ID NCT06955104
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This completed Phase 3 trial tested a combination of two drugs, JW0108 and C2407, in 145 adults with high cholesterol (dyslipidemia). The goal was to see if the combo lowers LDL ('bad') cholesterol more effectively and safely than placebo. Researchers measured changes in LDL levels from the start of the study.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- JW0108 and C2407 (two drugs combined)
- What this could lead to
- If it works, this could offer a new combination treatment to help control high cholesterol and reduce heart disease risk.
- What could go wrong
- This is a completed Phase 3 trial, but results are not yet published. The combination may not be more effective than existing treatments, and side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DYSLIPIDEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Asan Medical Center
Seoul, 05505, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Hormone therapy may shield menopausal hearts and brains — a trial puts it to the test
- Could vitamin d levels influence cholesterol in obese diabetes patients?
- Could a tropical oil and green exercise boost fat burning and calm your mind?
- Sugarcane supplement and exercise may team up to tame cholesterol
- Could a common cholesterol drug boost mood treatment?
- Could vinegar and fasting fix prediabetes cholesterol?